Views
999
Downloads
265
Get PDF
Get XML
Cite
Correspondence
Risks of testosterone therapy in elderly men [v1; ref status: indexed, http://f1000r.es/2oc]
Ranjith Ramasamy, James M. Dupree, Jason R. Kovac, Larry I. Lipshultz
Author affiliations
Grant information: The author(s) declared that no grants were involved in supporting this work.

Abstract

Testosterone supplementation therapy (TST) is a widely used treatment for men with late onset hypogonadism. The benefits seen with TST, such as improved libido and energy level, beneficial effects on bone density have been well documented. Although hypogonadism remains an independent risk factor for mortality, recent studies have examined the association between testosterone therapy and cardiovascular risk.

Correspondence

Vigen et al.1 examined the association between testosterone supplementation and cardiovascular morbidity in men older than 60 years. They performed a retrospective national cohort study of men with low testosterone levels (<300 ng/dL) who underwent coronary angiography in the Veterans Affairs (VA) system between 2005 and 2011. The absolute rate of atherosclerotic events (myocardial infarction, stroke and mortality) was 19.9% in men who did not receive testosterone vs 25.7% in the men who were treated with testosterone. Men on testosterone supplementation were reported to have higher risk of adverse events than men not on testosterone, despite being younger and having less comorbidity.

One of the most important messages to glean from the study is that hypogonadism could be an adverse prognostic factor for cardiovascular and cerebrovascular morbidity and mortality. This message is also found in other studies about hypogonadism, including a large study on male veterans that showed that hypogonadism could be an important risk factor for increased mortality2. Further, in men with hypertension3, low testosterone levels were shown to be associated with increased risk of major cardiovascular adverse events.

In the Vigen et al. study men who received testosterone had lower pre-therapy testosterone levels, suggesting that they were even more hypogonadal than men who did not start testosterone therapy.In addition, it is unclear how much testosterone the men in the treatment arm actually received. Based on prescription refills, most men were on testosterone therapy for less than one year, and their mean post-treatment testosterone level was 332 ng/dL. With serum testosterone less than 300 ng/dL defined as biochemical hypogonadism by the Endocrine Society4, we are concerned that a significant proportion of men could have remained hypogonadal, in spite of testosterone treatment.

Additionally, the reasons for starting testosterone therapy cannot be determined from this retrospective analysis. Because of the uncertain reasons for starting therapy in some hypogonadal men and not in others, and because of the variability in the amount of total testosterone that the patients actually received, there may be confounding factors that could also explain the higher risk of adverse events in men treated with testosterone. It is unclear whether the minimal exposure to testosterone in this elderly population (as evidenced by the post-treatment levels and duration of treatment) was responsible for such a dramatic difference in mortality and morbidity.

The association between testosterone therapy and mortality has remained controversial with studies demonstrating conflicting results5,6. Until larger randomized studies demonstrate clear causation, physicians prescribing testosterone therapy to elderly men with co-morbidities should use it prudently with close follow-up.

Open Peer Review

Current Referee Status: ?

Version 1
Views
40
Cite
Referee Report 23 Jan 2014
Matthew S. Wosnitzer Center for Male Reproductive Medicine and Surgery, Department of Urology and Institute for Reproductive Medicine, Weill Cornell Medical College of Cornell University, New York, NY, USA
Approved
This correspondence from the Baylor group accurately summarizes many of the questions surrounding the Vigen et al. article which describes an increased cardiovascular risk profile with testosterone replacement in a highly select group of VA patients. The majority of prior ... Continue reading
Views
28
Cite
Referee Report 22 Jan 2014
Boback Berookhim Memorial Sloan Kettering Cancer Center, New York, NY, USA
Approved
Dr. Ramasamy and colleagues present a well-researched brief summary on a topic which has received great attention among physicians treating low testosterone. The authors provide a nice summary of a newsworthy publication by Vigen et al. in JAMA in late ... Continue reading

Discuss this Article

Version 1
Alongside their report, referees assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - key revisions are required to address specific details and make the paper fully scientifically sound
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In

If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email info@f1000.com for further assistance.
Server error, please try again.